Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats

Psychopharmacology

Volumn 210, Issue 2, 2010, Pages 263-274

  Nemeth, Christina L ^a   Paine, Tracie A ^a   Rittiner, Joseph E ^b   Béguin, Cécile ^a   Carroll, F Ivy ^c   Roth, Bryan L ^b   Cohen, Bruce M ^a   Carlezon Jr , W A ^a  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Attention; Behavior; Kappa agonist; Model; Motivation; NMDA antagonist; Rat

Indexed keywords

KAPPA OPIATE RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SALVINORIN A; (3) 7 HYDROXY N [(1) 1 [[(3, 4) 4 (3 HYDROXYPHENYL) 3,4 DIMETHYL 1 PIPERIDINYL]METHYL] 2 METHYLPROPYL] 1,2,3,4 TETRAHYDRO 3 ISOQUINOLINECARBOXAMIDE; KAPPA OPIATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DISTURBANCE; CONTROLLED STUDY; MALE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BINDING; RESPONSE TIME; STIMULUS RESPONSE; ANIMAL TISSUE; ATTENTION; COGNITIVE DEFECT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG RECEPTOR BINDING; INSTRUMENTAL CONDITIONING; LATENT PERIOD; PERCEPTION DISORDER; PSYCHOPHARMACOLOGY; QUANTITATIVE ANALYSIS; TASK PERFORMANCE;

ANIMALS; ATTENTION; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; KETAMINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, KAPPA;

EID: 77953291406     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1834-7     Document Type: Article

References (58)

1. Amitai N, Semenova S, Markou A (2007) Cognitive disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications. Psychopharmacol 193: 521-537
2. Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (2009) Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacol 203: 203-211
3. Beardsley PM, Howard JL, Shelton KL, Carroll FI (2005) Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacol 183: 118-126
4. Carlezon WA Jr, Thomas M (2009) Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacol 56 (Suppl1): 122-132
5. Carlezon WA Jr, Béguin C, DiNieri JA, Baumann MH, Richards ME, Todtenkopf MS, Rothman RB, Ma Z, Y-W LD, Cohen BM (2006) Depressive-like effects of the κ-opioid receptor agonist Salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447
6. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (2004) Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203
7. Chen WJ, Faraone SV (2000) Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am J Med Genet 97: 52-57
8. Clark L, Iversen S, Goodwin G (2002) Sustained attention deficit in bipolar disorder. Br J Psychiatry 180: 133-139
9. Cornblatt BA, Malhotra AK (2001) Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet 105: 11-15
10. Crawford CA, McDougall SA, Bolanos CA, Hall S, Berger SP (1995) The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacol 120: 392-399
11. Davis JA (2008) Mouse and rat anesthesia and analgesia. Curr Protoc Neurosci 42: A.4B.1-A.4B.21
12. Fibiger HC, Fibiger HP, Zis AP (1973) Attenuation of amphetamine-induced motor stimulation and stereotypy by 6-hydroxydopamine in the rat. Br J Pharmacol 47: 683-692
13. Gonzalez D, Riba J, Bouso JC, Gómez-Jarabo G, Babanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85: 157-162
14. Hancock PJ, Stamford JA (1999) Stereospecific effects of ketamine on dopamine efflux and uptake in the rat nucleus accumbens. Br J Anaesth 82: 603-608
15. Hanes K (2001) Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 21: 634-635
16. Herberg LJ, Rose IC (1989) The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brainstimulation reward. Psychopharmacol 99: 87-90
17. Hetzler BE, Wautlet BS (1985) Ketamine-induced locomotion in rats in an open-field. Pharmacol Biochem Behav: 653-655
18. Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187: 555-556
19. Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ (2006) Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69: 338-345
20. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
21. Jensen NH, Roth BL (2008) Massively parallel screening of the receptorome. Comb Chem High Throughput Screen 11: 420-426
22. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidtae: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 20: 201-225
23. Knoll AT, Carlezon WA Jr (2010) Dynorphin, stress and depression. Brain Res 1314C: 56-73
24. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr (2007) Anxiolytic-like effects of κ-opioid receptor antagonists in behavioral models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323: 838-845
25. Kovács KJ, Larson AA (1998) Up-regulation of [3H]DTG but not [3H](+)-pentazocine labeled sigma sites in mouse spinal cord by chronic morphine treatment. Eur J Pharmacol 350: 47-52
26. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacol 169: 215-233
27. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacol 179: 303-309
28. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacol 25: 455-467
29. Leyton M, Stewart J (1992) The stimulation of central kappa opioid receptors decreases male sexual behavior and locomotor activity. Brain Res 594: 56-74
30. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2007) Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352
31. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr (2003) Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323-330
32. Maisonneuve IM, Archer S, Glick SD (1994) U50,488, a κ-opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181: 57-60
33. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C (2006) Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacol 31: 787-794
34. Mori T, Nomura M, Yoshizawa K, Nagase H, Sawaguchi T, Narita M, Suzuki. T (2006) Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of κ-opioid receptor agonists U-50,488H, but not TRK-820 in rats. J Pharmacol Sci 100: 157-161
35. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 5: 101-106
36. Paine T, Olmstead M (2004) Cocaine disrupts both behavioural inhibition and conditional discrimination in rats. Psychopharmacol 175: 443-450
37. Paine TA, Tomasiewicz HC, Zhang K, Carlezon WA Jr (2007) Sensitivity of the 5-choice serial reaction time task to the effects of various psychotropic drugs in Sprague-Dawley rats. Biol Psychiatry 62: 687-693
38. Paine TA, Neve RL, Carlezon WA Jr (2009) Attention deficits and hyperactivity following inhibition of cAMP-dependent protein kinase (PKA) within the medial prefrontal cortex of rats. Neuropsychopharmacol 34: 2143-2155
39. Parwani A, Weiler MA, Blaxton TA, Warfel D, Hardin M, Frey K, Lahti AC (2005) The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacol 183: 265-274
40. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776
41. Potter D, Toitman MF, Cohen BM, Carlezon WA Jr, Chartoff EH (2009) Biphasic effects of the kappa opioid receptor agonist salvinorin A on hedonic state. Soc Neurosci Abs 39: 564.14
42. Robbins T (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacol 163: 362-380
43. Rosvold HE, Mirsky AF, Saranson I, Bransome EB, Beck LH (1956) A continuous performance test of brain damage. J Consult Clin Psychol 20: 343-350
44. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Nat Acad Sci USA 99: 11934-11939
45. Shippenberg TS, LeFevour A, Heidbreder C (1996) kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276: 545-554
46. Siebert DJ (1994) Salvia divinorum and Salvinorin A: new pharmacologic findings. J Ethnopharmacol 43: 53-56
47. Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI (2003) Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R, 4R)-4-(3- hydroxyphenyl)3, 4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1, 2, 3, 4-tetrahydro-3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. J Med. Chem 46: 3127-3137
48. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr (2004) Effects of kappa-opioid receptor ligands on intracranial selfstimulation in rats. Psychopharmacol 172: 463-470
49. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr (2008) The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64: 982-988
50. Valdes LJ 3rd (1994) Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs 26: 277-283
51. Vortherms TA, Roth BL (2006) Salvinorin A: from natural product to human therapeutics. Molec Interv 6: 257-265
52. Wadenberg ML (2003) A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev 9: 187-198
53. Willmore-Fordham CB, Krall DM, McCurdy CR, Kinder DH (2007) The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacol 53: 481-486
54. Wise RA (2008) Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotoxicol Res 14: 169-183
55. Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, Wetsel WC, Mosier PD, Westkaemper RB, Allen JA, Zjawiony JK, Roth BL (2009) Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochem 48: 6898-6908
56. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864
57. Zhang J, Chiodo LA, Freeman AS (1992) Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res 590: 153-163
58. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacol 179: 551-558